Growth hormone (GH) dose-dependent IGF-I response relates to pubertal height gain

BMC Endocrine Disorders

Table 9 Multivariate analyses on height outcomes with all variables available

ITT	B	seb	P	R², %
Total gain in height_SDS
(Constant)	0.19	0.200	0.340	63
Prepubertal gain in height_SDS	0.55	0.085	0.000
Bone age delay at GH start	−0.25	0.072	0.001
∆IGF-I/IGFBP3 ratio_SDS 1 year after GH start	0.20	0.065	0.003
High dose	0.38	0.161	0.023
Pubertal gain in height_SDS
(Constant)	0.31	0.183	0.095	46
Bone age delay study start	−0.26	0.069	0.000
Years on GH prepubertal	−0.11	0.029	0.001
∆IGF-I_SDS 1 year after GH start	0.14	0.049	0.008
∆IGF-I_SDS pubertal level from study start	0.19	0.083	0.025
Prepubertal gain in height_SDS
(Constant)	−0.63	0.089	0.000	94
Years on GH, prepubertal	0.28	0.013	0.000
∆Height_SDS 1 year after GH start	0.69	0.074	0.000
∆IGF-I/IGFBP3ratio_SDS 1 year after GH start	0.12	0.029	0.000
Gender (female)	0.53	0.100	0.000
Bone age delay at GH start	−0.10	0.029	0.002
∆IGFBP3_SDS 1 year after GH start	0.14	0.062	0.030

A change, IGF-I insulin-like growth factor I, IGFBP3 IGF-binding protein 3, Ratio IGF-I/IGFBP3 Ratio, SDS standard deviation score

ISSN: 1472-6823